Clinical trial of SPL84-23 for muco-obstructive diseases and idiopathic pulmonary fibrosis
Latest Information Update: 11 Sep 2023
At a glance
- Drugs SPL 84 (Primary)
- Indications Idiopathic pulmonary fibrosis; Obstructive airway disorders
- Focus Adverse reactions
- Sponsors SpliSense
Most Recent Events
- 11 Sep 2023 New trial record
- 06 Sep 2023 According to a SpliSense media release, results from a phase 1/2 clinical trial in CF supports for further development of SPL84 for treatments for muco-obstructive diseases and idiopathic pulmonary fibrosis which are expected to enter the clinic next year.